Welcome to the Royal Philips Second Quarter Results 2014 Conference Call on Monday, 21 of July 2014. During the introduction hosted by Mr. Frans van Houten, CEO; and Mr. Ron Wirahadiraksa, CFO, all participants will be in a listen-only mode. After the introduction, there will be an opportunity to ask questions. (Operator Instructions). Please note that this call will be recorded and is available via webcast on the website of Royal Philips. I will now hand the conference over to Mr. Robin Jansen, Head of the Investor Relations. Please go ahead, sir.

Thank you. Good morning, ladies and gentlemen. And welcome to Philips’ second quarter results conference call. I’m here with Frans van Houten, CEO; and Ron Wirahadiraksa, CFO. In a moment, Frans will make his opening remarks and will take you through our main financial and strategic highlights for the period. Ron will then provide more details of the financial performance during the quarter. After that, both Frans and Ron will be happy take your questions. Our press release and the related information slide deck were published at 7:20 a.m. CT this morning. Both documents are now available for download from our Investor Relations website. A full transcript of this conference call will be made available by tomorrow on our Investor Relations website. And before I turn over the call to Frans, I would like to remind you of 2 things. Following the decision in Q1 2013 to sell the Audio, Video, Multimedia and Accessories business, or the AVM&A business, we reported a profit and loss on this business on the discontinued operations, and the net assets for the business in the balance sheet’s underlying assets held for sale. The cash flow of the Audio, Video, Multimedia and Accessories business is reported on the cash flow from discontinued operations. Therefore, all commentary that will follow in terms of sales and earnings at both the group level, as well as at the Consumer Lifestyle sector level, does not include AVM&A-related information. On June 29, 2014, the sale of this business to get some brands was completed. Secondly, when refer to adjusted EBITA on this call, this represents EBITA excluding restructuring costs, acquisition-related charges and other charges and gains above €20 million. With that, I would like to hand over the call to Frans.

Thanks Robin. Good morning and thank you for joining our second quarter 2014 conference call. As you have seen in our press release we achieved stable comparable sales growth at €5.3 billion with encouraging top-line results in growth geographies where sales increased by 4%. As expected, continued challenging market dynamics in the U.S., China and certain other emerging markets, as well as unfavorable currency exchange rates and the voluntary suspension of production healthcare facility in Cleveland, impacted our results as we focus on continuing to improve our fundamental performance. EBITDA was €450 million compared to €601 million in the second quarter of 2013. Excluding restructuring and acquisition related charges, EBITDA was €449 million or 8.5% of sales compared to 9.4% of sales in Q2 2013. Net income amounted to €243 million it was helped by lower tax expenses for which Ron will provide more detail, later on this call. While we were encouraged by some positive trends in each sector, and our operational performance is improving, we are not yet satisfied with these results. And we are taking further action to increase profitability as I will discuss in a moment. Let me give you first, a high-level overview of the performance per sector, starting with healthcare. Ongoing softness in certain markets, unfavorable currency exchange rates and the voluntary temporary suspension of production at the Cleveland facility continue to impact our performance this quarter with a 4% comparable sales growth decline and the low single-digit decrease in currency comparable for us. Geographically, we saw strong order intake in Europe, to growth geographies and most notably China, while order intake in the United States was down by double digits reflecting challenging market conditions and the production suspension at the Cleveland facility. The remediation program at the Cleveland facility is progressing according to…

Thank you, Frans. I will now provide you with some more details on our financial performance for the second quarter and some recent developments. Comparable sales in Q2 2014 were flat when adjusted for currency and portfolio changes. On a nominal basis, group sales decreased by 6% due to negative currency translation effects of 6%. Comparable sales in Western Europe were by and large flat, on the back of relative stable sales in Healthcare and low single-digit sales growth in Lighting and Consumer Lifestyle. Sales in North America declined mid single-digit on a comparable basis in the quarter, as healthcare sales declined high single-digit and Lighting declined low single-digit. Consumer Lifestyle delivered low single-digit growth in North America. The other mature geographies delivered low single-digit comparable sales growth. In our growth geographies, comparable sales grew by an encouraging 4% in the second quarter driven by double-digit growth in the majority of these growth geographies, which was partly offset by declines in countries like Russia, China and Thailand. Sales generated by the growth geographies represented 37% of total sales in line with Q2 of last year. In healthcare, comparable sales in the growth geographies decreased low single-digit in the quarter mainly driven by sales declines in China and Russia. Comparable healthcare sales in the mature markets were down mid single-digit. Western Europe showed flat sales growth with strong growth coming from countries like the U.K., France and Spain, while countries like Germany, Italy and the Benelux witnessed sales declines. In North America, Comparable sales were down high single-digit in the quarter partly due to marketing weakness. In Consumer Lifestyle, comparable sales in the growth geographies increased double-digit in the quarter. This was supported by most market and most notably China, India and Brazil. Sales in Western Europe and North America were…

Thank you, sir. (Operator Instructions). And your first question comes from Andreas Willi from JPMorgan. Please go ahead, sir. Andreas Willi – JPMorgan: Yes, good morning gentlemen. The first question is on guidance and communication to the market. You have provided quite specific guidance for the second half of the year. A few years ago, earlier in your tenure, you moved away from being that specific on short-term guidance, focusing more on the longer-term improvement. And I guess also because the business doesn’t have backlog, that kind of visibility, to give precise guidance. What underpins your second half-year guidance and how do you assess the risks around it? Is it more driven by your confidence in the cost savings coming through, or does it require a substantial improvement in demand? And, for example, what kind of sales growth in Healthcare would you need in the second half to deliver that improvement in adjusted – in EBITA year-on-year? Thank you.

Hi, good morning Andreas. Yes, we felt that giving a bit more guidance in these turbulent times was appropriate, helping everybody understand how we are doing. This underpinning of the second half and I presume you primarily are interested in healthcare is largely on the basis of order book on hand. You can imagine that was the resumption of the Cleveland plant, we are going to deliver on the backlog of orders. Many customers have been prepared to wait. I’m very thankful for that. And we will see a spike in deliveries especially in the fourth quarter. So, overall, underpinning looks fairly good. And I look now to my right, to see Ron sees would you like to add anything to this color on?

Yes. So, if you look at healthcare, as Frans said, we have a lot of catch-up demand coming in the second half. But I think we would need to be growing a little north of mid single-digits for healthcare to make that all happen. The underpinning of the slotting of the sales is very encouraging. And we see slightly better position than we were last year. Andreas Willi – JPMorgan: Thank you very much.

Okay, thanks.

Thank you. Our next question comes from Martin Wilkie from Deutsche Bank. Please go ahead, sir. Martin Wilkie – Deutsche Bank: Hi, good morning, it’s Martin from Deutsche Bank. Just a question on the changes you’ve seen in Healthcare. I was wondering if you could talk through why you’ve decided to set up the organization as you have done, taking out a layer of management, and whether that’s something we should expect elsewhere in the portfolio? And whether it’s also a signal of perhaps a review of the strategy or something like that inside Healthcare? Just if you could give us some idea as to why the decisions were made for the org changes as they were announced? Thank you.

All right, thanks Martin. Well, I can straight away fly that this is no change is strategy. I quite like this strategy in Healthcare to be focused on integral solutions along the continuum of care, helping large hospital systems to drive productivity from early diagnosis to minimally invasive intervention to patient monitoring and then even home care. So I think it’s a great space. And we want to be in it. Now, why did we intervene? Well, first of all let’s realize that performance wise, we were not at a level that we could be satisfied. The negative order intake trend started somewhere last year. Sales wise, the first half was really not great. And overall, on the accelerate journey, we can go faster. And now, taking out layer and having the three businesses report to me directly, I can imagine that people will ask what does that mean? But actually when you realize that the largest healthcare business imaging systems, that’s where the scanners and the diagnostic imaging equipment sits, that business group is larger than Consumer Lifestyle in its entirety. In other words, such an important deserves to be directly reporting to me. And I feel that with these moves, we can become more agile and decisive in moving forward, what is an extremely exciting time in healthcare technology. And we cannot sit on our sums, we need to move quickly forward and bring the healthcare businesses into the heart of Philips, is something that we think is a good move. And as such it doesn’t say anything about the other businesses, business and healthcare announcement where we intervene to step up performance of such an important business. Martin Wilkie – Deutsche Bank: Okay, thank you.

Thank you. Our next question comes from Ben Uglow from Morgan Stanley. Please go ahead. Ben Uglow – Morgan Stanley: Well, good morning Frans, good morning Ron.

Hi. Ben Uglow – Morgan Stanley: I had a couple of questions about Healthcare. First of all, just in China, it looks as though you’ve had a fairly significant order improvement during the quarter. Could you elaborate on that, is it broad based, was there any single, large order effect? And the trend that you’re currently seeing in China Healthcare is this something that you would expect to continue to improve over the second half of the year? What is your feeling on that geographic market in particular? So that was question number one. Question number two, I’m trying to understand the dynamics in the patient care business. It’s sort of double-digit order decline. Is that simply the market, or is this something to do with one or two particular competitors, has everybody else felt the same level of decline or is this down to Philips?

Okay, Ben, great question. So, let me start. In China, we saw for most of the first half of the year, a great reluctance of hospitals to award new orders. We believe that that in part is related to the climb down on corruption and much more, the carefulness in which administrative process is need to be done. Of course, second background reason is the overall slowdown of the economy. And late in the second quarter, we saw actually the order intake pick up again. If you recall in April, we talked about it being a delay rather than a cancellation. And we were in April hoping that it would come back. And actually it did with especially in the months of June, with stronger order intake. Now, then, your point is does that continue wasn’t it, Ben. I think we still need to brace ourselves for the slower market overall. So, I wouldn’t count that we are out of the woods completely now. I think it will remain a little bit bumpy. We will see how the third quarter develops before drawing stronger conclusions. But we are positively encouraged by the fact that order intake came back and we have such a strong market position in China as the market leader in that space. Then, your second question on Patient Care, Patient Care is a very good business for Philips. And we have a very strong market share. And I think this slowdown is also a little bit our own doing in the United States especially. If you recall the patient monitoring market, and although it is a global market, 50% of that market is actually in the United States, which is the more advanced from a technological point of view and more patients are being monitored there on a continuous basis. We have in the U.S. reorganized our sales force from basically a modality focused sales force to a more an enterprise key accounts sales force. We feel that that is necessary as hospitals will more and more to large scale projects and integrated buying versus individual commodity buying. And we think as in unintended consequence of that move is that we have dropped the ball a bit with less attention on this important category of patient monitoring. Thereby affectively slowing down the entire market because we are so large in the U.S. that if we slowdown, the market slows down. So, at this point we don’t think that we have lost market share. But the market share numbers for Q2 are not yet out. So, we still need to wait for that. But at this moment, we think it’s a little bit of self inflicted pain. And we would work very hard to repay it in the second half of the year. Ben Uglow – Morgan Stanley: That’s very helpful. Thank you.

Thanks.

Thank you. Our next question comes from Mark Troman from Bank of America Merrill Lynch. Please go ahead. Mark Troman – Bank of America Merrill Lynch: Yes, thank you. Good morning Frans, good morning Ron.

Hi. Mark Troman – Bank of America Merrill Lynch: Just got a question again on Healthcare, obviously, going into the second half. Frans, what improvements can you do very quickly, I mean, we’ve talked about slightly leaner overhead and but, ultimately, what is the scope to take significant levels of cost or gain significant levels of efficiency in this business? And how long would that take given, I guess, the FX and product lifecycles are longer in this business and lead times are longer in this business, than they are perhaps on the other divisions? And secondly, related to that, in terms of, how should we interpret the kind of increased restructuring savings? Is that more, is that all in Lighting and Healthcare or is there real emphasis on getting cost out of Healthcare post the weak Q2 results? Thank you.

Okay, hi Mark. Well, the improvements possible in Healthcare are multiple. First is the other sectors, Healthcare is not yet as far in implementing the Accelerate program. And therefore there is still a lot of unlocked potential. Overhead cost savings is still small part of that, actually I’m even more focused on the end-to-end effectiveness of the customer value chain. Indeed bringing products to the markets faster, applying these effects. But also shortening decision making cycles, improving accountability of results and getting more entrepreneurship in what still is somewhat conservative business. So I think that agility will have a positive effect. You’re right the healthcare business has somewhat longer cycles. Therefore we should also not count on having a magic turnaround in one quarter. It will take us several quarters to come back on the past to value. And we believe that therefore towards the 2016 targets, healthcare will be backend loaded between now and 2016 in realizing their objectives. Of course more to come at the Capital Markets Day, where we’re pretty sure we’ll come back on that topic. Now Mark, your second question, increased restructuring, did that apply to healthcare or to the whole group? Mark Troman – Bank of America Merrill Lynch: Well, both. I’m just trying to understand is the change that we’re seeing or the incremental gross savings, for example, is that mainly because of Healthcare or Lighting? Or how should we interpret that, in terms of where the incremental effort is going you’re reporting this quarter versus last?

Yes, hi, this is Ron, it’s a good question. So, of course we apply our overhead cost savings program across all sectors. But it is fair to say that Healthcare has been lagging a bit to what I would call it entitlement, what they should be doing. The same holds true for the effects. So what Frans is saying is, with bringing healthcare, BGs straight into the heart of Philips, we’re also and we said it are going to drive much stricter performance management. So make sure that these programs remain on track that there is no wavering or bailing out of targets. And the whole thing comes together in the second half much better than we have seen so far. So there will be an increased focus but otherwise the programs apply as you know with the Accelerate program across the whole company. Mark Troman – Bank of America Merrill Lynch: Okay. Thanks very much.

Thank you. Our next question comes from Gael De Bray with Societe Generale. Please go ahead. Gael De Bray – Societe Generale: Yes, good morning. Thank you very much. I have three questions, actually. Maybe one follow-up question regarding the new management structure at Healthcare, I take your point that imaging is actually maybe larger than the Consumer Lifestyle division. But the Light Sources business within Lighting is also as large as CL. So maybe what’s different at Healthcare which makes you not implement the same structure at Lighting? And question number two is on IG&S. The quarterly run rate has been much better in the first half of the year than what the full-year guidance would actually suggest. So what do you foresee for the second half at IG&S? And lastly for the Automotive Lighting business, I guess you’re probably the number one or number-two player there on traditional automotive lamps with Osram. But how do you assess your positioning on the automotive LED side, because it seems that some of the Taiwanese players have already significantly broken into the auto LED supply chains? So I guess I’d like to hear your thoughts on that, please.

Okay, I’ll take questions number one and three, Gael. And then I’ll let – ask Ron to do the second one. Let’s start with the follow-on on the management structure in Healthcare and what that would mean for other businesses. Look, we are intervening in Healthcare because we were not satisfied with the performance improvement, not just because the size of an individual business is of certain size. However, when people ask me then, would you consider re-implementing a sector leader to a Healthcare later on, I say no, because these businesses are so large and important that they actually deserve to be reporting directly into the CEO. Now, in Lighting, I consider that Eric Rondolat is doing a great job. He’s driving improvement in all of these businesses. So it’s not at all opportune to meddle with the structure. I’m not a great fan of structural changes because just reporting lines in his, own right are not always the solution. So it’s all about leadership and short decision cycles and impactful measures. And Eric Rondolat is doing as I said, a great job in driving that forward, so, no change there. If I move to the third question, Automotive Lighting and Lumileds will be moved together into a standalone company. And the reason for that is that Automotive Lighting or conventional lamps are also quickly moving to become LED components. And then the difference between Automotive LED and Lumileds becomes negligible. And in fact customers are looking for an integrated supply line, supply chain from R&D to manufacturing to supporting customers. And by making this move, we’re setting up both Lumileds and Automotive on a course of growth with lots of potential. We have been gaining market share in Automotive and not just in conventional but also in LED. And as we integrate these businesses further, we think that our customers will appreciate that and that we can, from a technology point of view, even drive further benefit to them. And Taiwanese players have not made a great in-road in the most critical automotive applications. It’s still more or less the traditional competitors in the automotive space which as you know are in part Japanese, German and Dutch, the latter ones being us of course. So, we look with confidence towards the future on Automotive Lighting. And with this integration and standalone setup, we will be able to attract outside investors. We hope that this company can grow rapidly, expand capacity and do win more customers. Ron, second one is for you.

Yes, so indeed, IG&S came better in the first half of the year as I said for Q2, that was mainly over-increased IP, royalties and lower cost in the IT service unit. So, we think with this performance, looking at the second half and also realizing that sometimes things come in a bit lumpy. The guidance is now 350, where it was first 380. Gael De Bray – Societe Generale: Okay. Thanks very much.

Thank you. Our next question comes from Olivier Esnou from Exane BNP Paribas. Please go ahead. Olivier Esnou – Exane BNP Paribas: Yes, hello, good morning. Thank you very much. My first question on the Healthcare recovery in the second half, I think heard well that you need above mid-single-digit growth in H2 for Healthcare, I guess that’s organic. And it’s above what I have seen in my numbers and consensus. Could you maybe separate out what has been the impact in H1 of Cleveland, and how much of that is actually into the H2 recoveries of growth? That’s the first question. Second question about the Conventional Lighting trends I think you said during the call that it’s declining 13%. I’m not sure if that’s last 12 month or year-to-date. Maybe you can just repeat that, I missed that? And I checked in your slide deck, I think your guidance is for high single-digit decline going forward versus previously a mid-single-digit decline guidance. Looking from here, what underpins your belief that it will go back to a less than double-digit decline and why it shouldn’t continue on that trend of double-digit? And maybe the third question regarding the strategy and operating steps. I mean, you’ve taken two big steps this quarter, on Lighting and the Healthcare management. You said you’re not a big fan of change. But when you mention the invite to the Capital Market Day, you said that you would update us on next strategy and operating steps in this journey. So I’m a bit wondering: is there another big step in Q3 or what you’re alluding at? Thank you very much.

Yes, Olivier, I’m smiling because of your last question but I’ll come to that in a moment. Let me start by giving Ron the chance to comment on the Healthcare recovery and to compare between H1 and H2.

Yes. So, I think Olivier to answer your question on what the impact of Cleveland is, it’s about 200 basis points in the growth around that. Olivier Esnou – Exane BNP Paribas: Okay.

Yes, so that should help the second quarter of course as we recover second half.

Second half.

Thank you. Okay, second question has to do with the Conventional Lighting decline. Indeed, we saw 11% decline in Q1, 13% decline in Q2. It does look like an accelerated decline indeed. We in our own modeling, we expect that decline to slightly taper off to around high single-digit. Of course the model assumes many variables. We still count on an overall LED penetration by 2015 of 45%. So we have not seen a dramatic shift there. What also has played into the conventional decline is a relatively high stock in trade for certain categories, notably in China. And that has kind of pushed up the decline temporarily. As we think, as we expect that stock in trade to normalize if and when that happens, then that would be a reason why the conventional decline could normalize at high single digit. Nevertheless, given that we have increased the decline rate from what we previously guided from a mid-to-high single-digit to a high single-digit. We are pulling in our restructuring plans and restructuring plans that were basically into drawer already. But we are now taking a bit further action already this year. And therefore we have raised the restructuring forecast for the second half here from €100 million to €170 million. Now then, the one that made me smile strategy and next operating steps. And I said, I’m not keen to only look at organizational structure and that didn’t have much strategic importance that remark. It’s more that if you change reporting lines that does not automatically improve performance. Now, somebody reports to another guy or girl that in its, own right is not performance improvement. That was the background of my remark and it is a remark that I’ve made often inside of Philips as guiding people against only re-hanging departments to other people. So, I believe in fundamental performance improvement, this is why we have here the Accelerate program, end-to-end and so on. So, don’t read anything specific into that little job. Now of course, Capital Market Days are always worth your attendance. And we will always have something to say. We do flat that we will be giving more detail on next strategic and operational steps basically as we are now firmly into the second half of our accelerate journey and there is more to come. Olivier Esnou – Exane BNP Paribas: Okay. So rendezvous there I guess, because it’s, but could it be at the same magnitude of the two recent announcements, or it’s more of an update?

So rendezvous alone Olivier. Olivier Esnou – Exane BNP Paribas: Okay, so I’ll wait for that. Thank you very much.

Thank you. Our next question comes from Simon Toennessen from Credit Suisse. Please go ahead with your question. Simon Toennessen – Credit Suisse: Yes, good morning gentlemen. The first question I have on the Healthcare market in Asia. I mean, looking at the order trends you’ve seen, and I think you have this on slide 62 in your slide deck where you can see the rest of the world and part of that is obviously Asia. But also knowing how you’ve grown in China last year, I would have assumed that sales in Asia should have been quite strong still for 2014 given the order trends. If I do a simple math and look at the share of Asia Pacific Healthcare sales, you obviously provide that pie chart in the slide deck. And I look at Q2 last year was 27%, now it’s 25%, and doing the math on that, you must have declined by around 16% in Asia in sales this quarter. Q1 was minus 14%. Is the majority of that just FX driven i.e., that which has taken off the big hit, or is there anything else that I’m might be missing? Second point is on the bridge. You provide that bridge on a Group level for EBITA, which is very helpful. Ron, could you maybe give us just a quick overview of how that minus 730-basis point drop in margins, how that roughly works out? We know pricing is 3% to 4%, but maybe you can give us a bit more help how this has looked. And then the last question, just on Cleveland again at the impact. You said earlier, minus 200 basis points. Is that minus 200 basis points on the minus 17% roughly in orders that you are showing in the slide deck, or of the high-single digit decline on sales? Thanks very much.

Yes, so thanks for the question. So, on the latter I was asked what is the impact of Cleveland in the first half in sales, so that’s around 200 basis points. I hope that clarifies. Simon Toennessen – Credit Suisse: Could you say what it was in Q2 on orders, relative to the minus 17% roughly you’ve seen?

I think it’s also around 2%. Simon Toennessen – Credit Suisse: Okay, thanks.

Yes.

It’s not much higher. Then your question on Healthcare, you mentioned Asia-Pac and then you said it’s 27% of total healthcare sales. But I believe that’s the emerging geographies anyway but they give you a little bit of color on the CSG in Q2. So, India was 9%, China was minus 13% in Q2. Bhutan was 6%, Russia and Central Asia minus 35% and then the others were up 10%. So that provides for the total growth geographies of, am I saying this right here? That’s the CSG. So, total geographies come down to minus 3% for Healthcare.

So that’s a little bit wider explanation. So Asia-Pac, as you saw it on the Slide 61, as all the Asia countries inside them, right, also China. So and India, and difficult things that sometimes are not defined under Asia-Pac. So that explains the CSG, I hope that’s an answer to your question. Then you said into bridge, 730 basis points margin decrease, which goes from 940 basis points adjusted EBITDA to 850 basis points. Simon Toennessen – Credit Suisse: No, I just meant the reported margin. So you had 17.8% in Q2 last year and then 10.5% this year. If you prefer doing it on underlying, that’s absolutely fine as well. Obviously, you had the one-off impacts from the gain and the pension impact last year.

Yes, exactly. But that’s the main driver. So the pension gain, and we sold our business in Healthcare. Is it understandable, because you’re talking Healthcare I guess? Simon Toennessen – Credit Suisse: I was just wondering whether you can just, in terms of basis points, give us the rough, if I’m not missing anything, obviously the volume declines then the gain if you take in the reported.

So, you’re looking for the Healthcare bridge on as the specification of the bridge that we have given, is that your question? Simon Toennessen – Credit Suisse: Basically, a bit more guidance on that, yes.

Yes, okay. So, we’ve given this bridge and that we haven’t given it by cycle. But I can’t talk about it a bit directionally. So of course Healthcare has negative volume impact. Now we want to surprise you with the percentages that we gave and you can multiple that basically on the nominal sales of last year, then you’ll get a good proxy. Then, price and wage inflation healthcare, price decreased, price erosion is not outside the 3% to 4% range. I think it’s even below 3%. So, of course as we always say, we don’t get each and every deal in. So, inside our order portfolio, price erosion maybe a little better than you would see in the general markets could be. And then, wage inflation for Healthcare is around 2.5% to 3%. Then if you look at the cost of goods, as I already have said, Healthcare does its bit. But it’s – it has to do better. So there is not a spectacular development there. And it’s not enough yet to offset the inflation and the price decrease. On overhead productivity savings, as you see on the bridge. Well, Healthcare contributes but as I also earlier said, below par. So, I’m talking really directionally with you. And then the impact of Healthcare in currency was around €40 million that I can tell you. Then of course on the right hand side, you see the Cleveland impact which is for the group the figure of €51 million but that only pertains to Healthcare. So, I think that gives you by and large the main building blocks of the adjusted EBITDA variance in Healthcare. Simon Toennessen – Credit Suisse: That was very helpful. Thank you very much.

Thank you.

Thank you. Our next question comes from Fredric Stahl from UBS. Please go ahead with your question. Fredric Stahl – UBS: Hello, Fredric here from UBS. Could I ask you in Consumer Lifestyle, do you have the same scope to drive growth from geographic expansion that you’ve had over the last few years? Or are you becoming more dependent on finding new product families or new avenues to the market, like your digital investments?

Hi Fredric. Well, we continue to be very optimistic about the opportunities for CL to drive growth. Admittedly the current growth rate is a little bit down from the growth rates that we saw in 2012 and early 2013, 7% of course very respectable. And there is a reflection in there that the emerging markets are a bit slower from – in their economy, China slower the South East Asia countries are slower. We do believe that Russia is obviously slower. So, despite all that slowdown we are still making 7% growth. And so, it’s a very healthy business and we continue to believe that it will be able to grow high-single digits on a – mid-to-high single-digits on a structural basis. And that is driven by both geographical expansion as well as product line extensions. Fredric Stahl – UBS: But there’s not change there from what you can see now?

No, nothing, no change whatsoever. Fredric Stahl – UBS: Okay, very good, thank you.

Thank you. Our next question comes from Daniela Costa from Goldman Sachs. Please go ahead. Daniela Costa – Goldman Sachs: Thanks for taking my questions. The first one, just to follow up, sorry, on the Cleveland impact on orders of 200 basis points, I think you mentioned for Healthcare, U.S. market overall for the year relatively flattish. Given if the impact on orders was 200 basis points, then I guess you were still well into double-digit territory for the quarter. Should we see, was the market as well at those levels, or were there market share variations and should we expect on market overall a big pickup in the second half? Just wanted to clarify how we read that. And then the second thing, can you talk a little bit about the improvements in the European Healthcare equipment order? So growing mid-single digit, where exactly does that come from? Is that related with comps being easier or there’s really an underlying trend there? And the third thing, just to clarify, so the headwind from FX in EBIDTA they were lower in Q2 versus Q1, how should we see it for the rest of the year, especially given the move in your hedging or some of your hedges may be rolling off? Thank you very much.

Hi. Yeah, overall in Healthcare, we do believe that our market share has been a little bit under pressure. Of course this also relates to the earlier discussion on performance in Healthcare and the need to intervene and to drive performance stronger. This is especially in relation to imaging systems. And the modalities that we manufacture in Cleveland are of course the most affected from the rest. As we resume shipments in the second half year, I think we are then on a course to repair that. And thus, we don’t think there is anything that cannot be repaired. We have very competitive product. We have some great products in the pipeline in imaging, just launched the new ultrasound machine. We have the Varios coming, the Spectral CT coming, so there is plenty to do. It will take us a couple of quarters to repair the trend-line. On Europe Healthcare, we earlier already quoted in the speech of Ron that the various markets show very different growth rates. And off the top of my head, Germany was a bit down whereas the Southern European counties were up. And I do believe that Southern Europe coming back is structural and it’s a good sign. But of course they come from a very low base. I mean, compared to 6 to 7 years ago, these markets are coming from half of what they formally were. So, there is a lot of growth opportunity as people give themselves the opportunity to upgrade hospitals. So, I do think that Europe is on a gradual path of improvement but it will still be a bumpy ride. On the ForEx situation, we need to distinguish two things. We saw that the impact in Q1 was 180 basis points the impact in Q2 was 80 basis points. And Ron already mentioned that in the second half of the year, the compare becomes easier. That means as the currencies were already sliding in the second half of last year. So therefore, we will see a smaller currency impact on a year-by-year comparison basis. That is notwithstanding the fact that we all believe that the Euro is still too expensive and we are battling this expensive Euro. And it affects our results. But of course we take many measures to offset it and improve our results regardless. Daniela Costa – Goldman Sachs: Thank you.

Thank you. Our next question comes from James Moore of Redburn. Please go ahead with your question. James Moore – Redburn Partners: Hi, good morning everyone, good morning Frans, Ron. Thanks for taking the questions. I’ve got three if I could? Firstly, on your 2016 outlook comment, I know that you’ve dropped the very confident language that you used last quarter. I want to check is that deliberate and are you a little less confident in 2016 or is it just an accident? Secondly, how much do you expect next year’s LED margin to increase to offset the delusionary effect of less traditional business, I presume we’ve got to lift the margin, let’s say from mid-single to high-single. And aside from the increased restructuring how confident are you on keeping fixed costs fixed in the LED business, and what are the risks here, if you could just talk a little bit around that. And thirdly, can you help us understand the size of the Cleveland impact better. You gave the €51 million and the €32 million numbers for the last two quarters. I just want to understand what those numbers are. Are they cost numbers or loss numbers? So do they take into account the loss sales effect or not and if not, can you size that? And also can you say relative to the €51 million what the impact will be in the stub quarter of the third quarter as you partially ramp up? Thanks.

Thank you. On the outlook, we are firmly committed towards our 2013 targets. On the LED margin, the LED business has many short segments. The components business, we have been doing a great job at expanding margins, that was a loss giving business a few years ago and we have recovered fantastically. And now we believe it’s a very healthy business. I’m bringing up the recollection just to make the point that it is possible to make good money in LED. It’s just that you need to hit the right levers to do so. When we look at the applications or the downstream market in LED, Professional Lighting, for us already has better gross margins than Conventional Lighting. This is very good news. And the fact that the Professional LED Lighting is not yet as profitable, it’s because we spend more R&D in it. But the gross margin is better than Conventional. So therefore, structurally it’s a good profit pool in the making. Now that leaves then the Lamps business and in the Lamps business we see strong price erosion, which is also necessary in order to make it a mainstream application with this fast consumer adoption, so that is the most turbulent of businesses where we have more work to be done before it is attractive profitable business. And especially in the Lamps area, we will have to reduce cost further. And in terms of modeling the Lighting sector, we will over time see a lower non-manufacturing cost base in order to maintain good profit margins that we are ambitious on. Yes, then the Cleveland question I hope that I can look to Ron for further elucidation.

Yes, thanks. So, of course it’s a combination both between sales and remediation cost. It’s of all the things that are in there sales plays an important role. Yes, but you see the recovery. I think in Q3, we’re not completely out of the woods yet but it will be better in making a less negative impact than in Q2, that’s the guidance I would give. And I think Q4 will make up for that shall we stay for the full year with €60 million to €70 million that we earlier guided for. James Moore – Redburn Partners: I understand, thank you. And just going back to the LED lamps specifically, what do you assume for the LED lamps EBIT margin in broad terms? Do you think that can go up next year basically? And does it have to go up a lot for you to really hit your overall Lighting target?

Well, both Ron and I love granularity but it doesn’t always mean that we can be as granular in a call like this. But, clearly, margins in Lighting will continue to improve that is what we have promised you. We have clear 2016 targets. We are on track to achieve that. And that includes the portfolio and makeshift that is taking place in Lighting, so no worries there, just keep diligently improving all our businesses. And let’s also not forget that next year we get the full-year benefit of both Consumer Luminaires and Professional Lighting North America, in which this year is making improvement on their turnaround, first half being still negative, second half becoming profitable as we promised. And then next year we have the full-year benefit of that. So that should help in modeling out ongoing improvement trend for next year. Now what is the – let’s say the thing that of course weighs on the Lighting performance, is the restructuring of the conventional base, where given the faster decline of Conventional. We are stepping up and pulling in some of the restructuring programs. And in that light, raising the second half of this year from €100 million to €170 million, and maybe a little bit more to come also, next year would be prudent to take into account when judging next year’s performance. James Moore – Redburn Partners: I see. Thank you very much.

You’re welcome.

Thank you. Our next question comes from Andrew Carter from RBC. Please go ahead. Andrew Carter – RBC Capital Markets: Good morning. And I had a couple of questions please. Just, first of all, on Cleveland, could you just talk a little bit more about the restart of that facility? Is that something that you can do at any time, or are you actually waiting for some particular regulatory approvals? And I guess just sort of follow-on on that would be, are there any other factories that you’ve had a look at anywhere and found any similar issues to what you found at Cleveland? And then the second one was still on Healthcare. And in the statement that you put out a couple of weeks ago you were talking about paradigm shift there. And I was just wondering what you were referring to specifically, and does that paradigm shift have any sort of impact on the competitive landscape that Healthcare faces?

Okay, great questions. So, the Cleveland shutdown is a voluntary shutdown. We took it on our own accord in order to remediate certain quality controls in manufacturing and procurement and in the design transfers. We have made great progress in fixing these issues. We believe we are now at the tail end for the first product – for the repair on the first product. And we think that we will be able to gradually resume production in the third quarter. And then the subsequent products will come through the rest of the year. So it is not that all of the product lines are back in production at the same time, you should see it as a gradual resumption where line after line they would be brought up to speed. That is a decision that we take ourselves, as we believe that our quality management system is back on track. We are being helped by independent auditors that we have invited one of our own accord to do a validation of our quality management system and to see whether it can stand the scrutiny of third party eyes. We are at the tail end of that audit validation. And that gives us belief that we’re on the right track. And therefore we make the statement with confidence that manufacturing can restart soon. Of course we have taken the Cleveland situation as a trigger to double scrutinize every other healthcare facility. You may recall that earlier in the year we also had some quality issues in our Andover facility. So, overall, I’m keen to step up what we call internally Philips excellence as the label for the quality standards that we set in all the healthcare sites by the way also CL and Lighting are doing that. I want to have…

Thank you. Our next question comes from Margaret Paxton from Berenberg. Please go ahead. Margaret Paxton – Berenberg: Good morning, gentlemen. Thanks for taking the questions. I’ve just got a few on Lighting please. The first one is could you just talk a little bit about the progression and pricing pressure in each conventional and LED lamps separately, has there been any change over the past few quarters, any alleviation or even acceleration? And then secondly, you said Consumer Luminaires would be break-even this year, you’ve also said that you see double-digit profitability potential in Professional Luminaires. Would you be willing to say the same about Consumer, or would it be maybe a slightly lower margin potential there, and maybe in what timeframe would you be looking to reach that? And then the last one on LED Lamps, given the Asian players are looking to enter this market, do you feel like you’re losing share in LED lamps specifically? Thanks.

All right. Let me start with the Consumer Luminaires business while we look up a little bit more data on the pricing question. Consumer Luminaires is actually a high gross margin business. It’s just that the sales level in Europe is too low to get a good bottom line return. With that answer, I’m implying that it can also become a good EBITDA business once the volumes get back up and we have finished with the non-manufacturing cost, the sales organization and what have you. Let’s not forget that the European market is deeply affected by the economic crisis and consumers are not shifting house, they are not buying lamps and luminaries as they used to. So, this business unit as it becomes now a much leaner business unit, it would be set up well when the market recovers in Europe, especially given those very attractive gross margins on the LED Luminaires. So, yes, eventually it should be in the same ballpark as the way we talk about professional Lighting Solutions. Then, the Asian competition, in fact it is nothing new if you compare it to CFL Lamps. So the compact fluorescent lighting lamps is also an Asia dominated supply market. And we source many of these CFL Lamps and are able to make good margins on it, given our strength in innovation, our strength in the brand and distribution. And I would see that same for let’s say the bread and butter Consumer Lamps categories. Of course it’s a different answer when it comes to Professional Lighting because there innovation plays such a big role that’s where we expect all the lighting to become connected. And we will see far less Asian players coming in. Ron, can I ask you to talk about the price pressure?

Of course, any pressure.

Any pressure.

Yes. So, if you look at the price pressure in Q1 in Lighting it was 2% to 3%. We saw some elevation indeed, some acceleration in Q2 it was closer to 3% to 4%. Of course, as LED Lamps continue to grow that will be a bigger part in the price erosion. Bear in mind that we have across the roadmaps in place that in principle tends to keep a good integral margin as we have it today. So, we’re working of course to sustain that. But yes, there would be somewhat higher price erosion driven by the uptake in LED Lamps particularly. Margaret Paxton – Berenberg: Thank you. So you’re saying Conventional is reasonably stable?

It’s reasonably – yes, it’s reasonably stable. So because as you know, and we have been quite advanced in ramping down the conventional footprint, through earlier also, two years ago, quite significant pull about restructuring, something we are about to do now for exactly the same reason to keep in mind with what we still as somewhat of a golden tail. Margaret Paxton – Berenberg: All right, thank you very much.

Thank you. Our final question comes from Hans Slob from Rabobank. Please go ahead. Hans Slob – Rabobank: Yes, good morning, thanks for taking my questions. Firstly, you have decided to combine lumileds and automotive into one single company, I think you indicated that this will lead to €30 million of integration costs. Are these included in the €170 million restructuring costs for the second half, that’s my first question? And second is the use of the Dutch Innovation Tax box. What will this mean for your tax rate guidance for 2014 and beyond? Thanks.

Yes, so the €30 million costs for Lumileds and Automotive in 2014 is not included in the €170 million restructuring. So it’s on top of. And the Innovation Box, we’ll have an impact of about 200 basis points on the ETR. So, the guidance will be anywhere between; 28% to 30% for this year in ETR.

Down from earlier 30% to 32%. Hans Slob – Rabobank: Okay, thanks, very helpful.

Thank you.

Thank you, Mr. van Houten, Mr. Wirahadiraksa. There are no further questions. Please continue.

Okay. Well, thanks for a great set of questions from in a very engaged call. I hope to see you all at the Capital Markets Day in September in London. Thanks very much.